智通财经APP获悉,远大医药(00512)再涨超8%,月内累计涨幅超35%。截至发稿,涨7.9%,报8.06港元,成交额2.86亿港元。
消息面上,远大医药近日发布多则利好,公司自主研发的全球创新药物STC3141在中国开展的用于治疗脓毒症的II期临床研究成功达到临床终点;用于治疗前列腺癌的全球创新放射性核素偶联药物(RDC) TLX591 (177Lu- HuJ591)加入国际多中心III期临床试验的申请已获得国家药监局受理。
中金发布研报称,由于脓毒症目前缺乏对因治疗手段,远大医药STC3141构建免疫稳态机制具备差异化,展示出具有临床意义的获益,有望为脓毒症带来新的治疗方案。同时,此前公司深耕呼吸及危重症领域,院内重症急救产品线完善,若STC3141未来得以商业化,将和公司现有管线形成良好的协同。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.